In summary, evidence on early HER-2-positive gastric cancer seems to point in the direction of a combination of chemotherapy, single HER-2 inhibition, either with trastuzumab or disitamab vedotin according to the current trials, with the eventual addition of ICIs. Here, ERBB2 is linked to gastric cancer.